<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugs_disease_country/PMC7265527/results/search/disease/results.xml">
  <result pre="UKLondon pmcid: 726552716585 doi: 10.1038/s41467-020-16585-y : Article Modeling mitigation of" exact="influenza" post="epidemics by baloxavir DuZhanwei1NugentCiara2GalvaniAlison P.3http://orcid.org/0000-0002-3754-5034KrugRobert M.4http://orcid.org/0000-0002-5828-8874MeyersLauren Ancellaurenmeyers@austin.utexas.edu125[1], 0000 0004"/>
  <result pre="worldwide. Antivirals can reduce death tolls. Baloxavir, the recently approved" exact="influenza" post="antiviral, inhibits initiation of viral mRNA synthesis, whereas oseltamivir,"/>
  <result pre="impact. Consequently, scaling up early baloxavir treatment would substantially reduce" exact="influenza" post="morbidity and mortality every year. The development of antivirals"/>
  <result pre="a mathematical model that describes how Baloxavir antiviral-induced inhibition of" exact="influenza" post="virus replication in infected individuals affects the spread of"/>
  <result pre="the scaling up and acceleration of treatment would avert substantial" exact="influenza" post="morbidity and mortality every year. Subject terms Diseases Health"/>
  <result pre="Introduction Influenza A and B viruses cause a highly contagious" exact="respiratory disease" post="in humans that kills 290,000–650,000 people worldwide every year1."/>
  <result pre="worldwide every year1. Vaccination is the primary means for controlling" exact="influenza" post="transmission but is hampered by the variable efficacy and"/>
  <result pre="after they develop symptoms. Prior to 2018, the only approved" exact="influenza" post="antivirals were viral neuraminidase inhibitors2,3. Of these, only oseltamivir"/>
  <result pre="shorten symptoms. In addition to reducing the duration of symptoms," exact="influenza" post="antivirals can reduce infectiousness by shortening the period of"/>
  <result pre="that scaling up and accelerating baloxavir treatment would substantially reduce" exact="influenza" post="morbidity and mortality every year. Results and discussion Impact"/>
  <result pre="discussion Impact of antiviral treatment on the cell-to-cell proliferation of" exact="influenza" post="Our within-host model assumes that infected patients have an"/>
  <result pre="recent clinical trial8 that measured the viral loads of 1014" exact="influenza" post="virus-infected patients after treatment with oseltamivir, baloxavir, or a"/>
  <result pre="data, and, like the clinical data, shows that baloxavir inhibits" exact="influenza" post="virus replication more effectively than oseltamivir (Fig. 1). Within"/>
  <result pre="are estimated via approximate Bayesian computation38,39 fitting of stochastic population-level" exact="influenza" post="transmission model (Supplementary Section 1) to US seasonal influenza"/>
  <result pre="population-level influenza transmission model (Supplementary Section 1) to US seasonal" exact="influenza" post="incidence data12. Parameters for distributions of time between infection"/>
  <result pre="dose. Impact of baloxavir treatment on the transmission dynamics of" exact="influenza" post="We incorporated this viral replication model into a stochastic"/>
  <result pre="this viral replication model into a stochastic individual-based model of" exact="influenza" post="transmission that tracks the daily evolution of infectiousness with"/>
  <result pre="viral load, treatment status, and baseline transmission rates estimated from" exact="influenza" post="surveillance data12,13 (Supplementary Table 2). Consistent with previous studies14,15,"/>
  <result pre="days. Fig. 2 Early antiviral treatment reduces the infectiousness of" exact="influenza" post="virus. Reduction of infectiousness by treatment with a baloxavir"/>
  <result pre="accelerating antiviral treatment, we fit our model to the 2017–2018" exact="influenza" post="epidemic in the United States, a severe epidemic which"/>
  <result pre="within 48 h after symptoms onset reduces the expected number of" exact="influenza" post="infections throughout the virus season by 38% or 26%,"/>
  <result pre="Baloxavir treatment is predicted to reduce the overall burden of" exact="influenza" post="more than oseltamivir treatment across all treatment rates. If"/>
  <result pre="are fit to incidence data from the 2016–2017 and 2018–2019" exact="influenza" post="seasons in the United States (Supplementary Figs. 4 and"/>
  <result pre="~1.08 (95% CI 1.05, 1.10). Fig. 3 Mitigation of seasonal" exact="influenza" post="with mass antiviral treatment. a Observed incidence of influenza"/>
  <result pre="seasonal influenza with mass antiviral treatment. a Observed incidence of" exact="influenza" post="virus (red) based on US surveillance data from the"/>
  <result pre="virus (red) based on US surveillance data from the 2017–2018" exact="influenza" post="season compared with typical model simulations without any antiviral"/>
  <result pre="in Table 1. Using our model based on the 2017–2018" exact="influenza" post="season, we consider the population-level impacts of treatment initiation"/>
  <result pre="and antiviral treatment can significantly mitigate the burden of seasonal" exact="influenza" post="in the United States. Using an influenza transmission model"/>
  <result pre="burden of seasonal influenza in the United States. Using an" exact="influenza" post="transmission model fitted to a recent clinical trial and"/>
  <result pre="onset. Consequently, efforts to accelerate the diagnosis and treatment of" exact="influenza" post="infections with antivirals such as baloxavir, including potentially cost-saving"/>
  <result pre="of 20–30% of infected patients may be attainable in future" exact="influenza" post="epidemics. Influenza A viruses also cause periodic widespread pandemics"/>
  <result pre="with oseltamivir and baloxavir that we have estimated for seasonal" exact="influenza" post="epidemics should extend to pandemics, although the herd effect"/>
  <result pre="oseltamivir (Supplementary Fig. 6). Seminal studies of the mitigation of" exact="influenza" post="pandemics suggest that oseltamivir-based interventions can only partially mitigate"/>
  <result pre="scaling up and acceleration of baloxavir treatment would avert substantial" exact="influenza" post="morbidity and mortality every year. Even modest baloxavir treatment"/>
  <result pre="baloxavir treatment rates can potentially spare millions of people from" exact="influenza" post="virus infections during epidemics, thereby substantially reducing hospitalizations, morbidity,"/>
  <result pre="as telemedicine and the development of rapid, sensitive assays for" exact="influenza" post="virus infection. Methods Our hierarchical method includes three steps"/>
  <result pre="1): (i) fitting a within-host model of antiviral-induced inhibition of" exact="influenza" post="virus replication to clinical trial data to estimate the"/>
  <result pre="fitting a between-host model of person-to-person virus transmission to seasonal" exact="influenza" post="surveillance data to estimate influenza transmission rates, and (3)"/>
  <result pre="person-to-person virus transmission to seasonal influenza surveillance data to estimate" exact="influenza" post="transmission rates, and (3) incorporate both sets of estimates"/>
  <result pre="and accelerating antiviral treatment during emerging epidemics. Within-host model of" exact="influenza" post="A replication dynamics We applied a published model that"/>
  <result pre="replication dynamics We applied a published model that includes viral" exact="suppression" post="by both the immune response and antiviral treatment10,11, as"/>
  <result pre="most of the patients in the trial were infected by" exact="influenza" post="A viruses, ~10% were infected by influenza B viruses."/>
  <result pre="were infected by influenza A viruses, ~10% were infected by" exact="influenza" post="B viruses. When we consider the reduced efficacy of"/>
  <result pre="viruses. When we consider the reduced efficacy of baloxavir against" exact="influenza" post="B viruses relative to influenza A viruses42, the predictions"/>
  <result pre="reduced efficacy of baloxavir against influenza B viruses relative to" exact="influenza" post="A viruses42, the predictions are relatively unchanged (Supplementary Fig."/>
  <result pre="placebo and treatment throughout the entire period of viremia. Between-host" exact="influenza" post="transmission models Using approximate Bayesian computation38,39, we fit a"/>
  <result pre="to incidence time series for the 2016–2017, 2017–2018, and 2018–2019" exact="influenza" post="seasons in the United States to estimate seasonal transmission"/>
  <result pre="product of CDC-reported ILINet activity and WHO lab percent positive" exact="influenza" post="tests12,13. We then incorporated viral replication dynamics and antiviral"/>
  <result pre="product of a population-wide scaling factor Φ estimated from seasonal" exact="influenza" post="incidence data and the individual’s infectiousness at time t"/>
  <result pre="the assumptions and robustness of the model with respect to" exact="influenza" post="virus type. Estimating epidemiological quantities from simulation data R0:"/>
  <result pre="CDC reported estimated for number of infections during the 2017–2018" exact="influenza" post="season12,13. DALYs averted To estimate the DALYs averted by"/>
  <result pre="cases, we estimate the years averted owing to alleviation of" exact="influenza" post="symptoms using baloxavir or oseltamivir8 (Supplementary Section 5). Reporting"/>
  <result pre="Food and Drug Administration. FDA approves new drug to treat" exact="influenza" post="(FDA, 2018). 5.PlotchSJBouloyMKrugRMTransfer of 5′-terminal cap of globin mRNA"/>
  <result pre="(FDA, 2018). 5.PlotchSJBouloyMKrugRMTransfer of 5′-terminal cap of globin mRNA to" exact="influenza" post="viral complementary RNA during transcription in vitroProc. Natl Acad."/>
  <result pre="transcription in vitroProc. Natl Acad. Sci. USA1979761618162210.1073/pnas.76.4.1618287003 6.PlotchSJBouloyMUlmanenIKrugRMA unique cap(m7GpppXm)-dependent" exact="influenza" post="virion endonuclease cleaves capped RNAs to generate the primers"/>
  <result pre="transcriptionCell19812384785810.1016/0092-8674(81)90449-96261960 7.ReichSet al.Structural insight into cap-snatching and RNA synthesis by" exact="influenza" post="polymeraseNature201451636136610.1038/nature1400925409151 8.HaydenFGet al.Baloxavir marboxil for uncomplicated influenza in adults"/>
  <result pre="RNA synthesis by influenza polymeraseNature201451636136610.1038/nature1400925409151 8.HaydenFGet al.Baloxavir marboxil for uncomplicated" exact="influenza" post="in adults and adolescentsN. Engl. J. Med.201837991392310.1056/NEJMoa171619730184455 9.JohnTJSamuelRHerd immunity"/>
  <result pre="for ILI, national summary. CDChttps://gis.cdc.gov/grasp/fluview/fluportaldashboard.html (2018). 14.HandelABrownJStallknechtDRohaniPA multi-scale analysis of" exact="influenza" post="A virus fitness trade-offs due to temperature-dependent virus persistencePLoS"/>
  <result pre="between and within scales: environmental persistence and within-host fitness of" exact="avian influenza" post="virusesProc. Biol. Sci.20142812013305110.1098/rspb.2013.305124898369 16.Centers for Disease Control and Prevention."/>
  <result pre="and within scales: environmental persistence and within-host fitness of avian" exact="influenza" post="virusesProc. Biol. Sci.20142812013305110.1098/rspb.2013.305124898369 16.Centers for Disease Control and Prevention."/>
  <result pre="Biol. Sci.20142812013305110.1098/rspb.2013.305124898369 16.Centers for Disease Control and Prevention. Archived estimated" exact="influenza" post="illnesses, medical visits, hospitalizations, and deaths in the United"/>
  <result pre="illnesses, medical visits, hospitalizations, and deaths in the United States—2017–2018" exact="influenza" post="season (CDC, 2019). 17.Centers for Disease Control and Prevention."/>
  <result pre="life year (DALY) (WHO, 2020). 22.SahPMedlockJFitzpatrickMCSingerBHGalvaniAPOptimizing the impact of low-efficacy" exact="influenza" post="vaccinesProc. Natl Acad. Sci. USA20181155151515610.1073/pnas.180247911529712866 23.GranwehrBPIn acute uncomplicated influenza,"/>
  <result pre="Med.2018169JC6310.7326/ACPJC-2018-169-12-06330557416 24.MontoASWebsterRGInfluenza pandemics: history and lessons learnedTextb. Influenza20132203310.1002/9781118636817.ch2 25.LonginiIMContaining pandemic" exact="influenza" post="at the sourceScience20053091083108710.1126/science.111571716079251 26.LonginiIMJrHalloranMENizamAYangYContaining pandemic influenza with antiviral agentsAm."/>
  <result pre="learnedTextb. Influenza20132203310.1002/9781118636817.ch2 25.LonginiIMContaining pandemic influenza at the sourceScience20053091083108710.1126/science.111571716079251 26.LonginiIMJrHalloranMENizamAYangYContaining pandemic" exact="influenza" post="with antiviral agentsAm. J. Epidemiol.200415962363310.1093/aje/kwh09215033640 27.GermannTCKadauKLonginiIMJrMackenCAMitigation strategies for pandemic"/>
  <result pre="influenza with antiviral agentsAm. J. Epidemiol.200415962363310.1093/aje/kwh09215033640 27.GermannTCKadauKLonginiIMJrMackenCAMitigation strategies for pandemic" exact="influenza" post="in the United StatesProc. Natl. Acad. Sci. USA20061035935594010.1073/pnas.060126610316585506 28.ColizzaVBarratABarthelemyMValleronA-JVespignaniAModeling"/>
  <result pre="case and containment interventionsPLoS Med.20074e1310.1371/journal.pmed.004001317253899 29.FergusonNMet al.Strategies for mitigating an" exact="influenza" post="pandemicNature200644244845210.1038/nature0479516642006 30.KamalMAet al.Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology"/>
  <result pre="mitigating an influenza pandemicNature200644244845210.1038/nature0479516642006 30.KamalMAet al.Interdisciplinary pharmacometrics linking oseltamivir pharmacology," exact="influenza" post="epidemiology and health economics to inform antiviral use in"/>
  <result pre="drug-disease model describing the effect of oseltamivir neuraminidase inhibition on" exact="influenza" post="virus progressionAntimicrob. Agents Chemother.2015595388539510.1128/AAC.00069-1526100715 37.MeyersLAPourbohloulBNewmanMEJSkowronskiDMBrunhamRCNetwork theory and SARS: predicting"/>
  <result pre="40.JiangHet al.Preliminary epidemiologic assessment of human infections with highly pathogenic" exact="avian influenza" post="A (H5N6) virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods"/>
  <result pre="al.Preliminary epidemiologic assessment of human infections with highly pathogenic avian" exact="influenza" post="A (H5N6) virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods"/>
  <result pre="infections: a systematic reviewLancet Infect. Dis.2009929130010.1016/S1473-3099(09)70069-619393959 42.KoszalkaPTilmanisDRoeMVijaykrishnaDHurtABaloxavir marboxil susceptibility of" exact="influenza" post="viruses from the Asia-Pacific, 2012–2018Antiviral Res.2019164919610.1016/j.antiviral.2019.02.00730771405 43.Keeling, M. J."/>
  <result pre="mortality over a seasonal baselineEpidemiology20122382983810.1097/EDE.0b013e31826c2dda22992574 45.FoxSJMillerJCMeyersLASeasonality in risk of pandemic" exact="influenza" post="emergencePLoS Comput. Biol.201713e100574910.1371/journal.pcbi.100574929049288 46.Xiang, Y., Gubian, S., Suomela, B."/>
 </snippets>
</snippetsTree>
